
1. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2450-5. doi: 10.1016/j.bmcl.2011.02.058. 
Epub 2011 Feb 23.

Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5
antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.

Skerlj R(1), Bridger G, Zhou Y, Bourque E, Langille J, Di Fluri M, Bogucki D,
Yang W, Li T, Wang L, Nan S, Baird I, Metz M, Darkes M, Labrecque J, Lau G,
Fricker S, Huskens D, Schols D.

Author information: 
(1)Genzyme Corp., 153 Second Avenue, Waltham, MA 02451, USA.
renato.skerlj@genzyme.com

A novel series of CCR5 antagonists were identified based on the redesign of
Schering C. An SAR was established based on inhibition of CCR5 (RANTES) binding
and these compounds exhibited potent inhibition of R5 HIV-1 replication in
peripheral blood mononuclear cells.

Copyright Â© 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.bmcl.2011.02.058 
PMID: 21398122  [Indexed for MEDLINE]

